Latest News & Features
article
Recent Federal Circuit decisions have sown confusion among patent practitioners regarding core aspects of US patent law, including induced infringement, patent eligibility, written description, and enablement. Although the Supreme Court recently declined to provide needed clarity on patent eligibility in American Axle, it still has several opportunities in the coming months to address other critical issues for the LSPN community. 1 November 2022
Biotechnology
Developments in microbiome tech are aimed at reducing the need for antibiotics in livestock farming and have led to some notable patenting trends and requirements, explains Rosie McDowell of EIP. 27 October 2022
Generics
The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”. 26 October 2022
article
The firm has strengthened its Sheffield office with a senior patent attorney who joins from GlaxoSmithKline. 25 October 2022
Big Pharma
The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company. 25 October 2022
Americas
The complaint centres on profiling tech used in genetic analysis | Last year, 10x Genomics accused NanoString of infringing multiple patents related to spatial profiling. 24 October 2022
Big Pharma
Commission overturns one ALJ finding but affirms all others, agreeing that Wuhan Healthgen infringed Ventria's rice seed patent | Dispute concerns recombinant human proteins derived from genetically engineered rice. 20 October 2022
Americas
Lawsuit centred on methods for stapling tissue during surgery | Delaware federal jury found in favour of Rex Medical. 20 October 2022
Big Pharma
Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales. 18 October 2022
Biotechnology
Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere. 18 October 2022